Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice

Kai Mao, Gabriela Farias Quipildor, Tahmineh Tabrizian, Ardijana Novaj, Fangxia Guan, Ryan O. Walters, Fabien Delahaye, Gene B. Hubbard, Yuji Ikeno, Keisuke Ejima, Peng Li, David B. Allison, Hossein Salimi-Moosavi, Pedro J. Beltran, Pinchas Cohen, Nir Barzilai, Derek M. Huffman

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Diminished growth factor signaling improves longevity in laboratory models, while a reduction in the somatotropic axis is favorably linked to human aging and longevity. Given the conserved role of this pathway on lifespan, therapeutic strategies, such as insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibodies (mAb), represent a promising translational tool to target human aging. To this end, we performed a preclinical study in 18-mo-old male and female mice treated with vehicle or an IGF-1R mAb (L2-Cmu, Amgen Inc), and determined effects on aging outcomes. Here we show that L2-Cmu preferentially improves female healthspan and increases median lifespan by 9% (P = 0.03) in females, along with a reduction in neoplasms and inflammation (P ≤ 0.05). Thus, consistent with other models, targeting IGF-1R signaling appears to be most beneficial to females. Importantly, these effects could be achieved at advanced ages, suggesting that IGF-1R mAbs could represent a promising therapeutic candidate to delay aging.

Original languageEnglish (US)
Article number2394
JournalNature Communications
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

Somatomedin Receptors
IGF Type 1 Receptor
Somatomedins
insulin
mice
Aging of materials
antibodies
Monoclonal Antibodies
neoplasms
Intercellular Signaling Peptides and Proteins
Inflammation
vehicles
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Mao, K., Quipildor, G. F., Tabrizian, T., Novaj, A., Guan, F., Walters, R. O., ... Huffman, D. M. (2018). Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice. Nature Communications, 9(1), [2394]. https://doi.org/10.1038/s41467-018-04805-5

Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice. / Mao, Kai; Quipildor, Gabriela Farias; Tabrizian, Tahmineh; Novaj, Ardijana; Guan, Fangxia; Walters, Ryan O.; Delahaye, Fabien; Hubbard, Gene B.; Ikeno, Yuji; Ejima, Keisuke; Li, Peng; Allison, David B.; Salimi-Moosavi, Hossein; Beltran, Pedro J.; Cohen, Pinchas; Barzilai, Nir; Huffman, Derek M.

In: Nature Communications, Vol. 9, No. 1, 2394, 01.12.2018.

Research output: Contribution to journalArticle

Mao, K, Quipildor, GF, Tabrizian, T, Novaj, A, Guan, F, Walters, RO, Delahaye, F, Hubbard, GB, Ikeno, Y, Ejima, K, Li, P, Allison, DB, Salimi-Moosavi, H, Beltran, PJ, Cohen, P, Barzilai, N & Huffman, DM 2018, 'Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice', Nature Communications, vol. 9, no. 1, 2394. https://doi.org/10.1038/s41467-018-04805-5
Mao, Kai ; Quipildor, Gabriela Farias ; Tabrizian, Tahmineh ; Novaj, Ardijana ; Guan, Fangxia ; Walters, Ryan O. ; Delahaye, Fabien ; Hubbard, Gene B. ; Ikeno, Yuji ; Ejima, Keisuke ; Li, Peng ; Allison, David B. ; Salimi-Moosavi, Hossein ; Beltran, Pedro J. ; Cohen, Pinchas ; Barzilai, Nir ; Huffman, Derek M. / Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice. In: Nature Communications. 2018 ; Vol. 9, No. 1.
@article{cea551295a364446b3b2c5f5d0c9af1c,
title = "Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice",
abstract = "Diminished growth factor signaling improves longevity in laboratory models, while a reduction in the somatotropic axis is favorably linked to human aging and longevity. Given the conserved role of this pathway on lifespan, therapeutic strategies, such as insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibodies (mAb), represent a promising translational tool to target human aging. To this end, we performed a preclinical study in 18-mo-old male and female mice treated with vehicle or an IGF-1R mAb (L2-Cmu, Amgen Inc), and determined effects on aging outcomes. Here we show that L2-Cmu preferentially improves female healthspan and increases median lifespan by 9{\%} (P = 0.03) in females, along with a reduction in neoplasms and inflammation (P ≤ 0.05). Thus, consistent with other models, targeting IGF-1R signaling appears to be most beneficial to females. Importantly, these effects could be achieved at advanced ages, suggesting that IGF-1R mAbs could represent a promising therapeutic candidate to delay aging.",
author = "Kai Mao and Quipildor, {Gabriela Farias} and Tahmineh Tabrizian and Ardijana Novaj and Fangxia Guan and Walters, {Ryan O.} and Fabien Delahaye and Hubbard, {Gene B.} and Yuji Ikeno and Keisuke Ejima and Peng Li and Allison, {David B.} and Hossein Salimi-Moosavi and Beltran, {Pedro J.} and Pinchas Cohen and Nir Barzilai and Huffman, {Derek M.}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41467-018-04805-5",
language = "English (US)",
volume = "9",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice

AU - Mao, Kai

AU - Quipildor, Gabriela Farias

AU - Tabrizian, Tahmineh

AU - Novaj, Ardijana

AU - Guan, Fangxia

AU - Walters, Ryan O.

AU - Delahaye, Fabien

AU - Hubbard, Gene B.

AU - Ikeno, Yuji

AU - Ejima, Keisuke

AU - Li, Peng

AU - Allison, David B.

AU - Salimi-Moosavi, Hossein

AU - Beltran, Pedro J.

AU - Cohen, Pinchas

AU - Barzilai, Nir

AU - Huffman, Derek M.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Diminished growth factor signaling improves longevity in laboratory models, while a reduction in the somatotropic axis is favorably linked to human aging and longevity. Given the conserved role of this pathway on lifespan, therapeutic strategies, such as insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibodies (mAb), represent a promising translational tool to target human aging. To this end, we performed a preclinical study in 18-mo-old male and female mice treated with vehicle or an IGF-1R mAb (L2-Cmu, Amgen Inc), and determined effects on aging outcomes. Here we show that L2-Cmu preferentially improves female healthspan and increases median lifespan by 9% (P = 0.03) in females, along with a reduction in neoplasms and inflammation (P ≤ 0.05). Thus, consistent with other models, targeting IGF-1R signaling appears to be most beneficial to females. Importantly, these effects could be achieved at advanced ages, suggesting that IGF-1R mAbs could represent a promising therapeutic candidate to delay aging.

AB - Diminished growth factor signaling improves longevity in laboratory models, while a reduction in the somatotropic axis is favorably linked to human aging and longevity. Given the conserved role of this pathway on lifespan, therapeutic strategies, such as insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibodies (mAb), represent a promising translational tool to target human aging. To this end, we performed a preclinical study in 18-mo-old male and female mice treated with vehicle or an IGF-1R mAb (L2-Cmu, Amgen Inc), and determined effects on aging outcomes. Here we show that L2-Cmu preferentially improves female healthspan and increases median lifespan by 9% (P = 0.03) in females, along with a reduction in neoplasms and inflammation (P ≤ 0.05). Thus, consistent with other models, targeting IGF-1R signaling appears to be most beneficial to females. Importantly, these effects could be achieved at advanced ages, suggesting that IGF-1R mAbs could represent a promising therapeutic candidate to delay aging.

UR - http://www.scopus.com/inward/record.url?scp=85048756857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048756857&partnerID=8YFLogxK

U2 - 10.1038/s41467-018-04805-5

DO - 10.1038/s41467-018-04805-5

M3 - Article

VL - 9

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 2394

ER -